Strategic Partnerships Nutromics has existing investor and board-level engagement with medtech players and accelerators, including Dexcom Ventures and a new chair with deep U.S. commercialization experience. This suggests receptivity to collaboration, co-development, and distribution partnerships that can accelerate market entry and scale selling efforts.

Sepsis and Critical Care Opportunity Current programs include sepsis management and triage, with recent funding to develop a world-first sepsis patch. Target hospitals and ICUs focusing on sepsis management represent high-value, urgent sales opportunities for real-time molecular monitoring solutions.

Real-Time Monitoring Value The wearable lab-on-a-patch using DNA biosensors enables continuous, real-time molecular data, which can appeal to clinicians seeking rapid decision support. Position Nutromics as a clinically impactful platform that complements antibiotic stewardship, dose optimization, and rapid triage workflows.

Pivotal Growth Phase With substantial funding and a board with commercialization experience, Nutromics is entering a pivotal phase, signaling readiness for larger pilot deployments and multi-site trials. This creates short-term sales windows for enterprise contracts and long-term multi-facility deployments.

Adjacent Disease Targets Beyond vancomycin tracking, the pipeline includes sepsis and cardiology targets. This opens cross-sell opportunities to hospitals and labs that manage complex antimicrobial and critical-care regimens, enabling expansion from a single biomarker to multiplex sensing capabilities.